Advertisement

Caffeine

  • Jack E. James
Chapter

Abstract

Caffeine is the most widely consumed psychoactive substance in history. This chapter provides an overview of the effects of caffeine on human health and well-being, with particular reference to the chronic effects of dietary use. Consideration is given to the main sources of caffeine and prevailing patterns of usage; the pharmacology of the drug, including the main mechanism of action and the key processes of physical dependence and tolerance; and the psychopharmacology of caffeine, with particular attention to psychomotor performance and mood, and the processes of withdrawal and withdrawal reversal. Regarding health consequences, attention is first given to mental health and well-being. This is followed by considerations of physical health, including cardiovascular disease, cancer, maternal use, and potential adverse interactions between caffeine and other drugs. Attention is given to whether caffeine may be regarded as a drug of addiction, whether there is a safe level of consumption, and processes for reducing and quitting caffeine consumption. Claims concerning possible health benefits of habitual caffeine use are examined, with particular reference to Type 2 diabetes mellitus and Parkinson’s disease, and mention is made of the growing interest in compounds other than caffeine in caffeine beverages. In the final section, consideration is given to major threats to the integrity of caffeine science, a topic that has thus far received too little attention in the literature. The main conclusions are that dietary caffeine is harmful to health. In particular, periods of caffeine abstinence in habitual users have negative effects on psychomotor performance and mood; habitual use produces modest increases in blood pressure that probably have negative effects on population cardiovascular health; caffeine interacts adversely with some medicines, and use during pregnancy may increase the risk of spontaneous abortion and lower birth weight. In contrast, there is little or no satisfactory evidence of net benefits of dietary caffeine. The extensive involvement of industry in caffeine research raises serious questions concerning the current and continued integrity of caffeine science.

Keywords

Caffeine Dietary caffeine Blood pressure Pharmacology of caffeine Adenosine Physical dependence Withdrawal Tolerance Withdrawal reversal Performance Mood Sleep Wakefulness Diagnostic and Statistical Manual of Mental Disorders Cardiovascular disease Epidemiology Cancer Maternal use of caffeine Adverse drug interactions Safe levels of caffeine consumption Quitting caffeine Type 2 diabetes mellitus Parkinson’s disease Scientific integrity Conflict of interest Self-serving bias 

References

  1. 1.
    Abu-Zeid HA, Choi NW, Hsu PH (1981) Factors associated with risk of cancer of the colon and rectum. Am J Epidemiol 114:442Google Scholar
  2. 2.
    Agardh EE, Carlsson S, Ahlbom A, Efendic S, Grill V, Hammar N et al (2004) Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J Intern Med 255(6):645–652PubMedCrossRefGoogle Scholar
  3. 3.
    al’Absi M, Lovallo WR, McKey B, Sung BH, Whitsett TL, Wilson MF (1998) Hypothalamic-pituitary-adrenocortical responses to psychological stress and caffeine in men at high and low risk for hypertension. Psychosom Med 60:521–527PubMedGoogle Scholar
  4. 4.
    Als-Nielsen B, Chen W, Gluud C, Kjaergard LL (2003) Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? J Am Med Assoc 290:921–928CrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. Author, Washington, DCGoogle Scholar
  6. 6.
    Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15:617–631PubMedCrossRefGoogle Scholar
  7. 7.
    Arnaud MJ (1987) The pharmacology of caffeine. Prog Drug Res 31:273–313PubMedGoogle Scholar
  8. 8.
    Asal NR, Geyer JR, Risser DR, Lee ET, Kadamani S, Cherng N (1988) Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detection Prevention 13:263–279Google Scholar
  9. 9.
    Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE et al (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50:56–63PubMedCrossRefGoogle Scholar
  10. 10.
    Bak AA, Grobbee DE (1990) A randomized study on coffee and blood pressure. J Human Hypertens 4:259–264Google Scholar
  11. 11.
    Baker JA, Beehler GP, Sawant AC, Jayaprakash V, McCann SE, Moysich KB (2006) Consumption of coffee, but not black tea, is associated with decreased risk of premenopausal breast cancer. J Nutr 136:166–171PubMedGoogle Scholar
  12. 12.
    Baron JA, Gerhardsson-de-Verdier M, Ekbom A (1994) Coffee, tea, tobacco, and cancer of the large bowel. Cancer Epidemiol Biomarkers Prevention 3:565–570Google Scholar
  13. 13.
    Bernard ME, Dennehy S, Keefauver LW (1981) Behavioural treatment of excessive coffee and tea drinking: a case study and partial replication. Behav Ther 12:543–548CrossRefGoogle Scholar
  14. 14.
    Biaggioni I, Paul S, Puckett A, Arzubiaga C (1991) Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 258:588–593PubMedGoogle Scholar
  15. 15.
    Bichler J, Cavin C, Simic T, Chakraborty A, Ferk F, Hoelzl C et al (2007) Coffee consumption protects human lymphocytes against oxidative and 3-amino-1-methyl-5H-pyrido[4,3-b]indole acetate (Trp-P-2) induced DNA-damage: results of an experimental study with human volunteers. Food Chem Toxicol 45:1428–1436PubMedCrossRefGoogle Scholar
  16. 16.
    Bonita JS, Mandarano M, Shuta D, Vinson J (2007) Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res 55:187–198PubMedCrossRefGoogle Scholar
  17. 17.
    Brazier JL, Salle B (1981) Conversion of theophylline to caffeine by the human fetus. Seminars Perinatol 5:315–320Google Scholar
  18. 18.
    Bridge N (1893) Coffee-drinking as a frequent cause of disease. Trans Assoc Am Physicians 8:281–288Google Scholar
  19. 19.
    Bush A, Busst CM, Clarke B, Barnes PJ (1989) Effect of infused adenosine on cardiac output and systemic resistance in normal subjects. Br J Clin Pharmacol 27:165–171PubMedCrossRefGoogle Scholar
  20. 20.
    Carter AJ, O’Connor WT, Carter MJ, Ungerstedt U (1995) Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors. J Pharmacol Exp Ther 273:637–642PubMedGoogle Scholar
  21. 21.
    Cauli O, Morelli M (2005) Caffeine and the dopaminergic system. Behav Pharmacol 16:63–77PubMedCrossRefGoogle Scholar
  22. 22.
    Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B (2002) Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 40:1155–1163PubMedCrossRefGoogle Scholar
  23. 23.
    Centonze S, Boeing H, Leoci C, Guerra V, Misciagna G (1994) Dietary habits and colorectal cancer in a low-risk area. Results from a population-based case-control study in southern Italy. Nutr Cancer 21:233–246PubMedCrossRefGoogle Scholar
  24. 24.
    Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M et al (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 21:RC143PubMedGoogle Scholar
  25. 25.
    Chvasta TE, Cooke AR (1971) Absorption and emptying of caffeine from the human stomach. Gastroenterology 61:838–843PubMedGoogle Scholar
  26. 26.
    Chyou PH, Nomura AM, Stemmermann GN (1993) A prospective study of diet, smoking, and lower urinary tract cancer. Ann Epidemiol 3:211–216PubMedCrossRefGoogle Scholar
  27. 27.
    Clausson B, Granath F, Ekbom A, Lundgren S, Nordmark A, Signorello LB et al (2002) Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol 155:429–436PubMedCrossRefGoogle Scholar
  28. 28.
    Cnattingius S, Signorello LB, Anneren G, Clausson B, Ekbom A, Ljunger E et al (2000) Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med 343:1839–1845PubMedCrossRefGoogle Scholar
  29. 29.
    Cole P (1971) Coffee drinking and cancer of the lower urinary tract. Lancet 2:1335CrossRefGoogle Scholar
  30. 30.
    Coney AM, Marshall JM (1998) Role of adenosine and its receptors in the vasodilation induced in the cerbral cortex of the rat by systemic hypoxia. J Physiol 509:507–518PubMedCrossRefGoogle Scholar
  31. 31.
    Cunha RA, Ferré S, Vaugeois, J-M, Chen, J-F (2008) Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 14:1512–1524PubMedCrossRefGoogle Scholar
  32. 32.
    Dana J, Loewenstein G (2003) A social science perspective on gifts to physicians from industry. JAMA: J Am Med Assoc 290:252–255CrossRefGoogle Scholar
  33. 33.
    D’Avanzo B, La-Vecchia C, Franceschi S, Negri E, Talamini R, Buttino I (1992) Coffee consumption and bladder cancer risk. Eur J Cancer 28A:1480–1484PubMedCrossRefGoogle Scholar
  34. 34.
    Denaro CP, Brown CR, Jacob PI, Benowitz NL (1991) Effects of caffeine with repeated dosing. Eur J Clin Pharmacol 40:273–278PubMedCrossRefGoogle Scholar
  35. 35.
    Dlugosz L, Belanger K, Hellenbrand K, Holford TR, Leaderer B, Bracken MB (1996) Maternal caffeine consumption and spontaneous abortion: a prospective cohort study. Epidemiology 7:250–255PubMedCrossRefGoogle Scholar
  36. 36.
    Dumas M, Gouyon JB, Tenenbaum D, Michiels Y, Escousse A, Alison M (1982) Systematic determination of caffeine plasma concentrations at birth in preterm and full-term infants. Develop Pharmacol Ther 4:182–186Google Scholar
  37. 37.
    Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31–55PubMedCrossRefGoogle Scholar
  38. 38.
    Edwards G, Savva S (2001) ILSI Europe, the drinks industry, and a conflict of interest undeclared. Addiction 96:197–202PubMedCrossRefGoogle Scholar
  39. 39.
    Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R, Shaw K et al (2006) Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease. J Neurol Neurosurg Psychiatry 77:317–321PubMedCrossRefGoogle Scholar
  40. 40.
    Evans SM, Griffiths RR (1991) Dose-related caffeine discrimination in normal volunteers: individual differences in subjective effects and self-reported cues. Behav Pharmacol 2:345–356PubMedGoogle Scholar
  41. 41.
    Fennelly M, Galletly DC, Purdie GI (1991) Is caffeine withdrawal the mechanism of postoperative headache? Anesthesia Analgesia 72:449–453PubMedCrossRefGoogle Scholar
  42. 42.
    Fenster L, Eskenazi B, Windham GC, Swan SH (1991) Caffeine consumption during pregnancy and fetal growth. Am J Public Health 81:458–461PubMedCrossRefGoogle Scholar
  43. 43.
    Fenster L, Hubbard AE, Swan SH, Windham GC, Waller K, Hiatt RA et al (1997) Caffeinated beverages, decaffeinated coffee, and spontaneous abortion.[see comment]. Epidemiology 8:515–523PubMedCrossRefGoogle Scholar
  44. 44.
    Ferré S, Schwarcz R, Li XM, Snaprud P, Ögren SO, Fuxe K (1994) Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Psychopharmacology 116:279–284PubMedCrossRefGoogle Scholar
  45. 45.
    Fernandes O, Sabharwal M, Smiley T, Pastuszak A, Koren G, Einarson T (1998) Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. Reprod Toxicol 12:435–444PubMedCrossRefGoogle Scholar
  46. 46.
    Finn IB, Holtzman SG (1987) Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity. Psychopharmacology 93:428–434PubMedCrossRefGoogle Scholar
  47. 47.
    Folsom AR, McKenzie DR, Bisgard KM, Kushi LH, Sellers TA (1993) No association between caffeine intake and postmenopausal breast cancer incidence in the Iowa Women’s Health Study. Am J Epidemiol 138:380–383PubMedGoogle Scholar
  48. 48.
    Foxx RM (1982) Behavioral treatment of caffeinism: a 40-month follow-up. Behav Therapist 5:23–24Google Scholar
  49. 49.
    Foxx RM, Axelroth E (1983) Nicotine fading, self-monitoring and cigarette fading to produce cigarette abstinence or controlled smoking. Behav Res Ther 21:17–27PubMedCrossRefGoogle Scholar
  50. 50.
    Foxx RM, Brown RA (1979) Nicotine fading and self-monitoring for cigarette abstinence or controlled smoking. J Appl Behav Anal 2:111–125CrossRefGoogle Scholar
  51. 51.
    Foxx RM, Rubinoff A (1979) Behavioral treatment of caffeinism: reducing excessive coffee drinking. J Appl Behav Anal 12:344–355Google Scholar
  52. 52.
    France C, Ditto B (1992) Cardiovascular responses to the combination of caffeine and mental arithmetic, cold pressor, and static exercise stressors. Psychophysiology 29:272–282PubMedCrossRefGoogle Scholar
  53. 53.
    Franchetti P, Messini L, Cappellacci L, Grifantini M, Lucacchini A, Martini C, Senatore G (1994) 8-Azaxanthine derivatives as antagonists of adenosine receptors. J Med Chem 37:2970–2975PubMedCrossRefGoogle Scholar
  54. 54.
    Freestone S, Yeo WW, Ramsay LE (1995) Effect of coffee and cigarette smoking on the blood pressure of patients with accelerated (malignant) hypertension. J Human Hypertens 9:89–91Google Scholar
  55. 55.
    Friedman GD, van den Eeden SK (1993) Risk factors for pancreatic cancer: An exploratory study. Int J Epidemiol 22:30–37PubMedCrossRefGoogle Scholar
  56. 56.
    Fuller RW, Maxwell DL, Conradson, T-BG, Dixon CMS, Barnes PJ (1987) Circulatory and respiratory effects of infused adenosine in conscious man. Br J Pharmacol 24:309–17Google Scholar
  57. 57.
    Galletly DC, Fennelly M, Whitwam JG (1989) Does caffeine withdrawal contribute to postanaesthetic morbidity? [Letter to the editor]. Lancet 1:1335PubMedCrossRefGoogle Scholar
  58. 58.
    Garrett BE, Griffiths RR (1998) Physical dependence increases the relative reinforcing effects of caffeine versus placebo. Psychopharmacology 139:195–202PubMedCrossRefGoogle Scholar
  59. 59.
    Garrett BE, Holtzman SG (1994) Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction. Eur J Pharmacol 262:65–75PubMedCrossRefGoogle Scholar
  60. 60.
    Giannelli M, Doyle P, Roman E, Pelerin M, Hermon C (2003) The effect of caffeine consumption and nausea on the risk of miscarriage. Paediatr Perinatal Epidemiol 17:316–323CrossRefGoogle Scholar
  61. 61.
    Gilbert RM (1976) Caffeine as a drug of abuse. Wiley, New YorkGoogle Scholar
  62. 62.
    Graham TE, Sathasivam P, Rowland M, Marko N, Greer F, Battram D (2001) Caffeine ingestion elevates plasma insulin response in humans during an oral glucose tolerance test. Can J Physiol Pharmacol 79:559–565PubMedCrossRefGoogle Scholar
  63. 63.
    Green PJ, Suls J (1996) The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. J Behav Med 19:111–128PubMedCrossRefGoogle Scholar
  64. 64.
    Greenberg W, Shapiro D (1987) The effects of caffeine and stress on blood pressure in individuals with and without a family history of hypertension. Psychophysiology 24:151–156PubMedCrossRefGoogle Scholar
  65. 65.
    Gregg ME, Matyas TA, James JE (2002) A new model of individual differences in hemodynamic profile and blood pressure reactivity. Psychophysiology 39:64–72PubMedCrossRefGoogle Scholar
  66. 66.
    Griffiths RR, Bigelow GE, Liebson IA (1986) Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther 239:416–425PubMedGoogle Scholar
  67. 67.
    Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, Woodson PP (1990) Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther 255:1123–1132PubMedGoogle Scholar
  68. 68.
    Grosso LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B, Bracken MB (2001) Maternal caffeine intake and intrauterine growth retardation [erratum appears in Epidemiology 2001 Sep;12(5):517]. Epidemiology 12:447–455PubMedCrossRefGoogle Scholar
  69. 69.
    Hampl KF, Schneider MC, Ruttimann U, Ummenhofer W, Drewe J (1995) Perioperative administration of caffeine tablets for prevention of postoperative headaches. Can J Anaesthesia 42:789–792CrossRefGoogle Scholar
  70. 70.
    Hartley TR, Lovallo WR, Whitsett TL, Sung BH, Wilson MF (2001) Caffeine and stress: implications for risk, assessment, and management of hypertension. J Clin Hypertens 3:354–361CrossRefGoogle Scholar
  71. 71.
    Hartley TR, Sung BH, Pincomb GA, Whitsett TL, Wilson MF, Lovallo WR (2000) Hypertension risk status and effect of caffeine on blood pressure. Hypertension 36:137–1341PubMedCrossRefGoogle Scholar
  72. 72.
    Heatherley SV, Hancock KMF, Rogers PJ (2006) Psychostimulant and other effects of caffeine in 9- to 11-year-old children. J Child Psychol Psychiatry 47:135–142PubMedCrossRefGoogle Scholar
  73. 73.
    Heatherley SV, Hayward RC, Seers HE, Rogers PJ (2005) Cognitive and psychomotor performance, mood, and pressor effects of caffeine after 4:6 and 8 h caffeine abstinence. Psychopharmacology 178:461–470PubMedCrossRefGoogle Scholar
  74. 74.
    Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284PubMedCrossRefGoogle Scholar
  75. 75.
    Heuman J (1994) A look back on 1993. Tea Coffee Trade J 166:5–7Google Scholar
  76. 76.
    Hirose K, Niwa Y, Wakai K, Matsuo K, Nakanishi T, Tajima K (2007) Coffee consumption and the risk of endometrial cancer: evidence from a case-control study of female hormone-related cancers in Japan. Cancer Sci 98(3):411–415PubMedCrossRefGoogle Scholar
  77. 77.
    Hollingworth HL (1912) The influence of caffeine on mental and motor efficiency. Archiv Psychol 22:1–166CrossRefGoogle Scholar
  78. 78.
    Hollingworth HL (1912) The influence of caffeine on the speed and quality of performance in typewriting. Psychol Rev 19:66–73CrossRefGoogle Scholar
  79. 79.
    Holtzman SG, Finn IB (1988) Tolerance to behavioral effects of caffeine in rats. Pharmacol Biochem Behav 29:411–418PubMedCrossRefGoogle Scholar
  80. 80.
    Hughes JR, Higgins ST, Bickel WK, Hunt WK, Fenwick JW, Gulliver SB, Mireault GC (1991) Caffeine self-administration, withdrawal, and adverse effects among coffee drinkers. Archiv Gen Psychiatry 48:611–617CrossRefGoogle Scholar
  81. 81.
    Hughes JR, Oliveto AH, Bickel WK, Higgins ST, Badger GJ (1993) Caffeine self-administration and withdrawal: incidence, individual differences and interrelationships. Drug Alcohol Depend 32:239–246PubMedCrossRefGoogle Scholar
  82. 82.
    Hughes JR, Oliveto AH, Helzer JE, Higgins ST, Bickel WK (1992) Should caffeine abuse, dependence or withdrawal be added to DSM-IV and ICD-10? Am J Psychiatry 149:33–40PubMedGoogle Scholar
  83. 83.
    Hughes JR, Oliveto AH, Liguori A, Carpenter J, Howard T (1998) Endorsement of DSM-IV dependence criteria among caffeine users. Drug Alcohol Depend 52:99–107PubMedCrossRefGoogle Scholar
  84. 84.
    IARC (1991) Coffee, tea, mate, methylxanthines and methylglyoxal. IARC monograph evaluating carcinogenic risks to humans. WHO, UKGoogle Scholar
  85. 85.
    International Life Sciences Institute (2008) http://www.ilsi.org/memberportal/Shared/ContentMgt/Templates/OpenDetail.aspx?NRMODE=Published&NRORIGINALURL=/AboutILSI/IOC/IOCINFO.htm&NRNODEGUID={E553676A-0D56–4BF4-B5F3-D0D8F8078DEB}&NRCACHEHINT=NoModifyGuest&print=yes. Accessed on 30 July 2008Google Scholar
  86. 86.
    Jacobsen BK, Thelle DS (1987) The Tromso heart study: is coffee drinking an indicator of a life style with high risk for ischemic heart disease? Acta Medica Scandinavica 222:215–221PubMedCrossRefGoogle Scholar
  87. 87.
    Jacobsen B, Bjelke E, Kvåle G, Heuch I (1986) Coffee drinking, mortality, and cancer incidence: results from a Norwegian prospective study. J Natl Cancer Inst 76:823–831PubMedGoogle Scholar
  88. 88.
    James JE (1990) The influence of user status and anxious disposition on the hypertensive effects of caffeine. Int J Psychophysiol 10:171–179PubMedCrossRefGoogle Scholar
  89. 89.
    James JE (1991) Caffeine and health. Academic, LondonGoogle Scholar
  90. 90.
    James JE (1994) Psychophysiological effects of habitual caffeine consumption. Int J Behav Med 1:247–263PubMedCrossRefGoogle Scholar
  91. 91.
    James JE (1994) Chronic effects of habitual caffeine consumption on laboratory and ambulatory blood pressure levels. J Cardiovasc Res 1:159–164Google Scholar
  92. 92.
    James JE (1994) Does caffeine enhance or merely restore degraded psychomotor performance? Neuropsychobiology 30:124–125PubMedCrossRefGoogle Scholar
  93. 93.
    James JE (1994) Caffeine, health and commercial interests. Addiction 89:1595–1599PubMedCrossRefGoogle Scholar
  94. 94.
    James JE (1995) Caffeine, psychomotor performance and commercial interests: reply to Smith. Addiction 90:1262–1265CrossRefGoogle Scholar
  95. 95.
    James JE (1997) Understanding caffeine: a biobehavioral analysis. Sage, Thousand Oaks, CAGoogle Scholar
  96. 96.
    James JE (1997) Caffeine and blood pressure: habitual use is a preventable cardiovascular risk factor. Lancet 349:279–281PubMedCrossRefGoogle Scholar
  97. 97.
    James JE (1998) Acute and chronic effects of caffeine on performance, mood, headache, and sleep. Neuropsychobiology 38:32–41PubMedCrossRefGoogle Scholar
  98. 98.
    James JE (2002) “Third party” threats to research integrity in public-private partnerships. Addiction 97:1251–1255PubMedCrossRefGoogle Scholar
  99. 99.
    James JE (2004) A critical review of dietary caffeine and blood pressure: a relationship that should be taken more seriously. Psychosom Med 66:63–71PubMedCrossRefGoogle Scholar
  100. 100.
    James JE, Gregg ME (2004) Hemodynamic effects of dietary caffeine, sleep restriction, and laboratory stress. Psychophysiology 41:914–923PubMedCrossRefGoogle Scholar
  101. 101.
    James JE, Gregg ME (2004) Effects of dietary caffeine on mood when rested and sleep restricted. Human Psychopharmacol: Clin Exp 19:333–341CrossRefGoogle Scholar
  102. 102.
    James JE, Gregg ME, Kane M, Harte F (2005) Dietary caffeine, performance and mood: enhancing and restorative effects after controlling for withdrawal relief. Neuropsychobiology 52:1–10PubMedCrossRefGoogle Scholar
  103. 103.
    James JE, Keane MA (2007) Caffeine, sleep and wakefulness: implications of new understanding about withdrawal reversal. Human Psychopharmacol: Clin Exp 22:549–558CrossRefGoogle Scholar
  104. 104.
    James JE, Richardson M (1991) Pressor effects of caffeine and cigarette smoking. Br J Clin Psychol 30:276–278PubMedCrossRefGoogle Scholar
  105. 105.
    James JE, Rogers PJ (2005) Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology 182:1–8PubMedCrossRefGoogle Scholar
  106. 106.
    James JE, Stirling KP, Hampton BAM (1985) Caffeine fading: behavioral treatment of caffeine abuse. Behav Ther 16:15–27CrossRefGoogle Scholar
  107. 107.
    James JE, Paull I, Cameron-Traub E, Miners JO, Lelo A, Birkett DJ (1988) Biochemical validation of self-reported caffeine consumption during caffeine fading. J Behav Med 11:15–30PubMedCrossRefGoogle Scholar
  108. 108.
    Jarvis MJ (1993) Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology 110:45–52PubMedCrossRefGoogle Scholar
  109. 109.
    Jeong D, Dimsdale JE (1990) The effects of caffeine on blood pressure in the work environment. Am J Hypertens 3:749–753PubMedGoogle Scholar
  110. 110.
    Judelson DA, Armstrong LE, Sokmen B, Roti MW, Casa DJ, Kellogg MD (2005) Effect of chronic caffeine intake on choice reaction time, mood, and visual vigilance. Physiol Behav 85:629–634PubMedCrossRefGoogle Scholar
  111. 111.
    Juliano LM, Griffiths RR (2004) A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology 176:1–29PubMedCrossRefGoogle Scholar
  112. 112.
    Julius S (1988) The blood pressure seeking properties of the central nervous system. J Hypertens 6:177–185PubMedCrossRefGoogle Scholar
  113. 113.
    Kaiser L, Allen LH, American Dietetic Association (2008) Position of the American dietetic association: nutrition and lifestyle for a healthy pregnancy outcome. J Am Dietetic Assoc 108:553–561CrossRefGoogle Scholar
  114. 114.
    Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D (1993) Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4:375–382PubMedCrossRefGoogle Scholar
  115. 115.
    Kalda A, Yu L, Oztas E, Chen JF (2006) Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson’s disease. J Neurol Sci 248:9–15PubMedCrossRefGoogle Scholar
  116. 116.
    Karatzis E, Papaioannou TG, Aznaouridis K, Karatzi K, Stamatelopoulos K, Zampelas A et al (2005) Acute effects of caffeine on blood pressure and wave reflections in healthy subjects: should we consider monitoring central blood pressure? Int J Cardiol 98:425–430PubMedCrossRefGoogle Scholar
  117. 117.
    Keane MA, James JE, Hogan MJ (2007) Effects of dietary caffeine on topographic EEG after controlling for withdrawal and withdrawal reversal. Neuropsychobiology 56:197–207PubMedCrossRefGoogle Scholar
  118. 118.
    Keijzers GB, De Galan BE, Tack CJ, Smits P (2002) Caffeine can decrease insulin sensitivity in humans.[see comment]. Diabetes Care 25:364–369PubMedCrossRefGoogle Scholar
  119. 119.
    Klesges RC, Ray JW, Klesges LM (1994) Caffeinated coffee and tea intake and its relationship to cigarette smoking: an analysis of the second national health and nutrition examination survey. J Subst Abuse 6:407–18PubMedCrossRefGoogle Scholar
  120. 120.
    LaCroix AZ, Mead LA, Liang KY, Thomas CB, Pearson TA (1987) Coffee consumption and coronary heart disease. N Engl J Med 316:947CrossRefGoogle Scholar
  121. 121.
    Lane JD (1994) Neuroendocrine responses to caffeine in the work environment. Psychosom Med 546:267–270Google Scholar
  122. 122.
    Lane JD (1997) Effects of brief caffeine deprivation on mood, symptoms, and psychomotor performance. Pharmacol Biochem Behav 58:203–208PubMedCrossRefGoogle Scholar
  123. 123.
    Lane JD, Adcock RA, Williams RB, Kuhn CM (1990) Caffeine effects on cardiovascular and neuroendocrine responses to acute psychosocial stress and their relationship to level of habitual caffeine consumption. Psychosom Med 52:320–336PubMedGoogle Scholar
  124. 124.
    Lane JD, Barkauskas CE, Surwit RS, Feinglos MN (2004) Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care 27:2047–2048PubMedCrossRefGoogle Scholar
  125. 125.
    Lane JD, Feinglos MN, Surwit RS (2008) Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes. Diabetes Care 31:221–222PubMedCrossRefGoogle Scholar
  126. 126.
    Lane JD, Hwang AL, Feinglos MN, Surwit RS (2007) Exaggeration of postprandial hyperglycemia in patients with type 2 diabetes by administration of caffeine in coffee. Endocrine Pract 13:239–243Google Scholar
  127. 127.
    Lane JD, Phillips-Bute BG (1998) Caffeine deprivation affects vigilance performance and mood. Physiol Behav 65:171–175PubMedCrossRefGoogle Scholar
  128. 128.
    Lane JD, Pieper CF, Phillips-Bute BG, Bryant JE, Kuhn CM (2002) Caffeine affects cardiovascular and neuroendocrine activation at work and home. Psychosom Med 64:595–603PubMedCrossRefGoogle Scholar
  129. 129.
    Lane JD, Williams RB (1987) Cardiovascular effects of caffeine and stress in regular coffee drinkers. Psychophysiology 24:157–164PubMedCrossRefGoogle Scholar
  130. 130.
    La Vecchia C, Franceschi S, Decarli A, Gentile A, Liati P, Regallo M, Tognoni G (1984) Coffee drinking and the risk of epithelial ovarian cancer. Int J Cancer 33:559–562PubMedCrossRefGoogle Scholar
  131. 131.
    La Vecchia C, Franceschi S, Decarli A, Parazzini F, Tognoni G (1986) Coffee consumption and the risk of breast cancer. Surgery 100:477–481PubMedGoogle Scholar
  132. 132.
    La Vecchia C, Ferraroni M, Negri E, D’Avanzo B, Decarli A, Levi F, Franceschi S (1989) Coffee consumption and digestive tract cancers. Cancer Res 49:1049–1051PubMedGoogle Scholar
  133. 133.
    La Vecchia C, Negri E, Decarli A, D’Avanzo B, Gallotti L, Gentile A, Franceschi S (1988) A case-control study of diet and colo-rectal cancer in northern Italy. Int J Cancer 41:492–498PubMedCrossRefGoogle Scholar
  134. 134.
    Lawson DH, Jick H, Rothman KJ (1981) Coffee and tea consumption and breast disease. Surgery 90:801–803PubMedGoogle Scholar
  135. 135.
    LeBlanc J, Soucy J (1994) Hormonal dose-response to an adenosine receptor agonist. Can J Physiol Pharmacol 72:113–116PubMedCrossRefGoogle Scholar
  136. 136.
    Lee S (1993) Carcinogens and mutagens. Tea Coffee Trade J January:5–6Google Scholar
  137. 137.
    LeGrady D, Dyer AR, Shekelle RB, Stamler J, Liu K, Paul O, Lepper M, Shryock AM (1987) Coffee consumption and mortality in the Chicago western electric company study. Am J Epidemiol 126:803–812PubMedGoogle Scholar
  138. 138.
    Lelo A, Miners JO, Robson R, Birkett DJ (1986) Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther 39:54–59PubMedCrossRefGoogle Scholar
  139. 139.
    Lelo A, Miners JO, Robson RA, Birkett DJ (1986) Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 22:183–186PubMedCrossRefGoogle Scholar
  140. 140.
    Lieberman HR, Wurtman RJ, Emde GG, Roberts C, Coviella ILG (1987) The effects of low doses of caffeine on human performance and mood. Psychopharmacology 92:308–312PubMedCrossRefGoogle Scholar
  141. 141.
    Lipinsky DP, Black JL, Nelson RO, Cimimero AR (1975) The influence of motivational variables on the reactivity and reliability of self-recording. J Consulting Clin Psychol 43:637–646CrossRefGoogle Scholar
  142. 142.
    Lovallo WR, Farag NH, Vincent AS, Thomas TL, Wilson MF (2006) Cortisol responses to mental stress, exercise, and meals following caffeine intake in men and women. Pharmacol Biochem Behav 83:441–447PubMedCrossRefGoogle Scholar
  143. 143.
    Lovallo WR, Pincomb GA, Sung BH, Passey RB, Suasen KP, Wilson MF (1989) Caffeine may potentiate adrenocortical stress responses in hypertension-prone men. Hypertension 14:170–176PubMedCrossRefGoogle Scholar
  144. 144.
    Lubin JH, Burns PE, Blot WJ, Ziegler RG, Lees AW, Fraumeni JF (1981) Dietary factors and breast cancer risk. Int J Cancer 28:685–689PubMedCrossRefGoogle Scholar
  145. 145.
    MacDonald R (2001) WHO says tobacco industry “used” institute to undermine its policies. Br Med J 322:576CrossRefGoogle Scholar
  146. 146.
    MacMahon B, Yen S, Trichopoulos D, Warren K, Nardi G (1981) Coffee and cancer of the pancreas. N Engl J Med 304:630–633PubMedCrossRefGoogle Scholar
  147. 147.
    MacMahon S (2000) Blood pressure and the risk of cardiovascular disease. N Engl J Med 342:50–2PubMedCrossRefGoogle Scholar
  148. 148.
    MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335:765–774PubMedCrossRefGoogle Scholar
  149. 149.
    Mahmud A, Feely J (2001) Acute effect of caffeine on arterial stiffness and aortic pressure waveform. Hypertension 38:227–231PubMedCrossRefGoogle Scholar
  150. 150.
    Mansel RE, Webster DJT, Burr M, Leger SS (1982) Is there a relationship between coffee consumption and breast disease? B J Surg 69:295–296Google Scholar
  151. 151.
    Marangos PJ, Boulenger JP (1985) Basic and clinical aspects of adenosinergic neuromodulation. Neurosci Biobehav Rev 9:421–430PubMedCrossRefGoogle Scholar
  152. 152.
    Martin JB, Annegers JF, Curb JD, Heyden S, Howson C, Lee ES, Lee M (1988) Mortality patterns among hypertensives by reported level of caffeine consumption. Prev Med 17:310–320PubMedCrossRefGoogle Scholar
  153. 153.
    Masterson J (1983) Trends in coffee consumption. Tea Coffee Trade J March:24–25Google Scholar
  154. 154.
    Menza M (2000) The personality associated with Parkinson’s disease. Curr Psychiatry Rep 2:421–426PubMedCrossRefGoogle Scholar
  155. 155.
    Michels KB, Holmberg L, Bergkvist L, Wolk A (2002) Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. Ann Epidemiol 12:21–26PubMedCrossRefGoogle Scholar
  156. 156.
    Michels KB, Willett WC, Fuchs CS, Giovannucci E (2005) Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst 97:282–292PubMedCrossRefGoogle Scholar
  157. 157.
    Mills JL, Holmes LB, Aarons JH, Simpson JL, Brown ZA, Jovanovic-Peterson LG, Conley MR, Graubard BI, Knopp RH., Metzger BE (1993) Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA: J Am Med Assoc 269:593–597CrossRefGoogle Scholar
  158. 158.
    Momas I, Daures JP, Festy B, Bontoux J, Gremy F (1994) Relative importance of risk factors in bladder carcinogenesis: some new results about Mediterranean habits. Cancer Causes Control 5:326–32PubMedCrossRefGoogle Scholar
  159. 159.
    Momoi N, Tinney JP, Liu LJ, Elshershari H, Hoffmann PJ, Ralphe JC et al (2008) Modest maternal caffeine exposure affects developing embryonic cardiovascular function and growth. Am J Physiol – Heart Circulatory Physiol 294:H2248–H2256CrossRefGoogle Scholar
  160. 160.
    Murphy P (2001) ILSI responds to March 10 BMJ article. Br Med J 322:576CrossRefGoogle Scholar
  161. 161.
    Nelson RO, Lipinsky DP, Black JL (1975) The effects of expectancy on the reactivity of self-recoding. Behav Ther 6:337–349CrossRefGoogle Scholar
  162. 162.
    Nikolajsen L, Larsen KM, Kierkegaard O (1994) Effect of previous frequency of headache, duration of fasting and caffeine abstinence on perioperative headache. Br J Anaesthesia 72:295–297CrossRefGoogle Scholar
  163. 163.
    Nishi M, Ohba S, Hirata K, Miyake H (1996) Dose-response relationship between coffee and the risk of pancreas cancer. Jpn J Clin Oncol 26:42–48PubMedCrossRefGoogle Scholar
  164. 164.
    Nomura A, Heilbrun LK, Stemmermann GN (1986) Prospective study of coffee consumption and the risk of cancer. J Natl Cancer Inst 76:587–590PubMedGoogle Scholar
  165. 165.
    Oberman Z, Harell A, Herzberg M, Hoerer E, Jaskolka H, Laurian L (1975) Changes in plasma cortisol, glucose and free fatty acids after caffeine ingestion in obese women. Israel J Med Sci 11:33–36PubMedGoogle Scholar
  166. 166.
    Olsen J, Kronborg O (1993) Coffee, tobacco and alcohol as risk factors for cancer and adenoma of the large intestine. Int J Epidemiol 22:398–402PubMedCrossRefGoogle Scholar
  167. 167.
    Patton GC, Hibbert M, Rosier MJ, Carlin JB, Caust J, Bowes G (1995) Patterns of common drug use in teenagers. Australian J Public Health 19:393–399CrossRefGoogle Scholar
  168. 168.
    Paul S, Kurunwune B, Biaggioni I (1993) Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets. J Pharmacol Exp Ther 267:838–843PubMedGoogle Scholar
  169. 169.
    Pearson TA (1999) Cardiovascular disease in developing countries: myths, realities, and opportunities. Cardiovasc Drugs Therapy 13:95–104CrossRefGoogle Scholar
  170. 170.
    Petrie HJ, Chown SE, Belfie LM, Duncan AM, McLaren DH, Conquer JA et al (2004) Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. Am J Clin Nutr 80(1): 22–28PubMedGoogle Scholar
  171. 171.
    Pfeifer RW, Notari RE (1988) Predicting caffeine plasma concentrations resulting from consumption of food or beverages: a simple method and its origin. Drug Intelligence Clin Pharm 22:953–959Google Scholar
  172. 172.
    Phillips-Bute BG, Lane JD (1998) Caffeine withdrawal symptoms following brief caffeine deprivation. Physiol Behav 63:35–39CrossRefGoogle Scholar
  173. 173.
    Pincomb GA, Lovallo WR, Passey RB, Brackett DJ, Wilson MF (1987) Caffeine enhances the physiological response to occupational stress in medical students. Health Psychol 6:101–112PubMedCrossRefGoogle Scholar
  174. 174.
    Pincomb GA, Lovallo WR, Passey RB, Wilson MF (1988) Effect of behavior state on caffeine's ability to alter blood pressure. Am J Cardiol 61:798–802PubMedCrossRefGoogle Scholar
  175. 175.
    Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913CrossRefGoogle Scholar
  176. 176.
    Rakic V, Burke V, Beilin LJ (1999) Effects of coffee on ambulatory blood pressure in older men and women: a randomized controlled trial. Hypertension 33:869–873PubMedCrossRefGoogle Scholar
  177. 177.
    Rall TW (1990) Drugs used in the treatment of asthma. The methylxanthines, cromolyn sodium, and other agents. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. Pergamon, New York, pp 618–637Google Scholar
  178. 178.
    Rasch V (2003) Cigarette, alcohol, and caffeine consumption: risk factors for spontaneous abortion. Acta Obstetricia et Gynecologica Scandinavica 82:182–188PubMedCrossRefGoogle Scholar
  179. 179.
    Richards G (1994) Tea in 1993. Tea Coffee Trade J 166:42–50Google Scholar
  180. 180.
    Richardson NJ, Rogers PJ, Elliman NA, O’Dell RJ (1995) Mood and performance effects of caffeine in relation to acute and chronic caffeine deprivation. Pharmacol Biochem Behav 52:313–320PubMedCrossRefGoogle Scholar
  181. 181.
    Robertson D, Wade D, Workman R, Woosley RL, Oates JA (1981) Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 67:1111–1117PubMedCrossRefGoogle Scholar
  182. 182.
    Rodgers A, Lawes C, MacMahon S (2000) Reducing the global burden of blood pressure-related cardiovascular disease. J Hypertens 18:S3–S6CrossRefGoogle Scholar
  183. 183.
    Rodgers A, MacMahon S (1999) Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens 21:543–552PubMedCrossRefGoogle Scholar
  184. 184.
    Rogers PJ, Dernoncourt C (1998) Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. Pharmacol Biochem Behav 59:1039–1045PubMedCrossRefGoogle Scholar
  185. 185.
    Rogers PJ, Heatherley SV, Hayward RC, Seers HE, Hill J, Kane M (2005) Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction. Psychopharmacology 179:742–752PubMedCrossRefGoogle Scholar
  186. 186.
    Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW (2008) Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology 195:569–577PubMedCrossRefGoogle Scholar
  187. 187.
    Rohan TE, McMichael AJ (1988) Methylxanthines and breast cancer. Int J Cancer 41:390–393PubMedCrossRefGoogle Scholar
  188. 188.
    Rose J (1981) Strategy of prevention: lessons from cardiovascular disease. Br Med J 282:1847–1851CrossRefGoogle Scholar
  189. 189.
    Rosenberg L, Miller DR, Helmrich SP, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S (1985) Breast cancer and the consumption of coffee. Am J Epidemiol 122:391–399PubMedGoogle Scholar
  190. 190.
    Rosenberg L, Palmer JR, Kelly JP, Kaufman DW, Shapiro S (1988) Coffee drinking and nonfatal myocardial infarction in men under 55 years of age. Am J Epidemiol 128:570–578PubMedGoogle Scholar
  191. 191.
    Rosengren A, Dotevall A, Wilhelmsen L, Thelle D, Johansson S (2004) Coffee and incidence of diabetes in Swedish women: a prospective 18-year follow-up study. J Intern Med 255:89–95PubMedCrossRefGoogle Scholar
  192. 192.
    Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. [see comment]. JAMA: J Am Med Assoc 283:2674–2679CrossRefGoogle Scholar
  193. 193.
    Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitzmann MF, Stampfer MJ et al (2004) Coffee consumption and risk for type 2 diabetes mellitus. [see comment] [summary for patients in Ann Intern Med 2004 Jan 6;40(1):I17; PMID: 14706993]. Ann Inter Med 140:1–8Google Scholar
  194. 194.
    Sanguigni V, Gallu M, Ruffini MP, Strano A (1995) Effects of coffee on serum cholesterol and lipoproteins: the Italian brewing method. Italian group for the study of atherosclerosis and dismetabolic diseases, Rome II center. Eur J Epidemiol 11:75–78PubMedCrossRefGoogle Scholar
  195. 195.
    Santos IS, Victora CG, Huttly S, Morris S (1998) Caffeine intake and pregnancy outcomes: a meta-analytic review. Cadernos de Saude Publica 14(3):523–530PubMedCrossRefGoogle Scholar
  196. 196.
    Schairer C, Brinton LA, Hoover RN (1987) Methylxanthines and breast cancer. Int J Cancer 40:469–473PubMedCrossRefGoogle Scholar
  197. 197.
    Schiffman SS, Warwick ZS (1989) Use of flavor-amplified foods to improve nutritional status in elderly persons. New York Academy of Sciences, New YorkGoogle Scholar
  198. 198.
    Schreiber GB, Robins M, Maffeo CE, Masters MN, Bond AP, Morganstein D (1988) Confounders contributing to the reported associations of coffee or caffeine with disease. Prev Med 17:295–309PubMedCrossRefGoogle Scholar
  199. 199.
    Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr et al (2003) Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease. Neurology 61(Suppl 6):S55–S61PubMedCrossRefGoogle Scholar
  200. 200.
    Shepard JD, al’Absi M, Whitsett TL, Passey RB, Lovallo WR (2000) Additive pressor effects of caffeine and stress in male medical students at risk for hypertension. Am J Hypertens 13:475–781PubMedCrossRefGoogle Scholar
  201. 201.
    Shi J, Benowitz NL, Denaro CP, Sheiner LB (1993) Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 53:6–14PubMedCrossRefGoogle Scholar
  202. 202.
    Shibata A, Mack TM, Paganini-Hill A, Ross RK, Henderson BE (1994) A prospective study of pancreatic cancer in the elderly. Int J Cancer 58:46–49PubMedCrossRefGoogle Scholar
  203. 203.
    Shirlow. M. J., Berry G, Stokes G (1988) Caffeine consumption and blood pressure: an epidemiologic study. Int J Epidemiol 17:90–97PubMedCrossRefGoogle Scholar
  204. 204.
    Shu XO, Hatch MC, Mills J, Clemens J, Susser M (1995) Maternal smoking, alcohol drinking, caffeine consumption, and fetal growth: results from a prospective study. Epidemiology 6:115–20PubMedCrossRefGoogle Scholar
  205. 205.
    Slattery ML, West DW, Robison LM, French TK, Ford MH, Schuman KL, Sorenson AW (1990) Tobacco, alcohol, coffee, and caffeine as risk factors for colon cancer in a low-risk population. Epidemiology 1:141–145PubMedCrossRefGoogle Scholar
  206. 206.
    Slattery ML, Caan BJ, Anderson KE, Potter JD (1999) Intake of fluids and methylxanthine-containing beverages: association with colon cancer. Int J Cancer 81:199–204PubMedCrossRefGoogle Scholar
  207. 207.
    Smit HJ, Rogers PJ (2000) Effects of caffeine on cognitive performance, mood and thirst in lower and higher caffeine consumers. Psychopharmacology 152:167–173PubMedCrossRefGoogle Scholar
  208. 208.
    Smith SJ, Deacon JM, Chilvers CE (1994) Alcohol, smoking, passive smoking and caffeine in relation to breast cancer risk in young women. UK national case-control study group. Br J Cancer 70:112–119PubMedCrossRefGoogle Scholar
  209. 209.
    Smits P, Boekema P, de Abreu R, Thien T, van’t Laar A (1987) Evidence for an antagonism between caffeine and adenosine in the human cardiovascular system. J Cardiovasc Pharmacol 10:136–43PubMedCrossRefGoogle Scholar
  210. 210.
    Smits P, Temme L, Thien T (1993) The cardiovascular interaction between caffeine and nicotine in humans. Clin Pharmacol Ther 54:194–204PubMedCrossRefGoogle Scholar
  211. 211.
    Smits P, Thien T, van’t Laar A (1985) The cardiovascular effects of regular and decaffeinated coffee. Br J Clin Pharmacol 19:852–854PubMedCrossRefGoogle Scholar
  212. 212.
    Smits P, Thien T, van’t Laar A (1985) Circulatory effects of coffee in relation to the pharmacokinetics of caffeine. Am J Cardiol 56:958–963PubMedCrossRefGoogle Scholar
  213. 213.
    Snowdon DA, Phillips RL (1984) Coffee consumption and risk of fatal cancers. Am J Public Health 74:820–823PubMedCrossRefGoogle Scholar
  214. 214.
    Somani SM, Gupta P (1988) Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Ther Toxicol 26:521–533PubMedGoogle Scholar
  215. 215.
    Song YJ, Kristal AR, Wicklund KG, Cushing-Haugen KL, Rossing MA (2008) Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:712–716PubMedCrossRefGoogle Scholar
  216. 216.
    Spindel ER, Wurtman RJ, McCall A, Carr D, Conlay L, Griffith L, Arnold MA (1984) Neuroendocrine effects of caffeine in normal subjects. Clin Pharmacol Ther 36:402–407PubMedCrossRefGoogle Scholar
  217. 217.
    Spinillo A, Capuzzo E, Nicola SE, Colonna L, Egbe TO, Zara C (1994) Factors potentiating the smoking-related risk of fetal growth retardation. Br J Obstetrics Gynaecol 101:954–958CrossRefGoogle Scholar
  218. 218.
    Stafford LD, Yeomans MR (2005) Caffeine deprivation state modulates coffee consumption but not attentional bias for caffeine-related stimuli. Behav Pharmacol 16(7):559–571PubMedCrossRefGoogle Scholar
  219. 219.
    Stocks P (1970) Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee. Br J Cancer 24:215–225PubMedCrossRefGoogle Scholar
  220. 220.
    Streufert S, Pogash R, Miller J, Gingrich D, Landis R, Lonardi L, Severs W, Roache JD (1995) Effects of caffeine deprivation on complex human functioning. Psychopharmacology 118:377–384PubMedCrossRefGoogle Scholar
  221. 221.
    Superko HR, Myll J, DiRicco C, Williams PT, Bortz WM, Wood PD (1994) Effects of cessation of caffeinated-coffee consumption on ambulatory and resting blood pressure in men. Am J Cardiol 73:780–784PubMedCrossRefGoogle Scholar
  222. 222.
    Tavani A, Gallus S, Dal Maso L, Franceschi S, Montella M, Conti E et al (2001) Coffee and alcohol intake and risk of ovarian cancer: an Italian case-control study. Nutrition Cancer 39:29–34CrossRefGoogle Scholar
  223. 223.
    Tavani A, La Vecchia C (2004) Coffee, decaffeinated coffee, tea and cancer of the colon and rectum: a review of epidemiological studies, 1990–2003. Cancer Causes Control 15:743–757PubMedCrossRefGoogle Scholar
  224. 224.
    Todes CJ, Lees AJ (1985) The pre-morbid personality of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 48:97–100PubMedCrossRefGoogle Scholar
  225. 225.
    Trichopoulos D, Papapostolou M, Polychronopoulou A (1981) Coffee and ovarian cancer. Int J Cancer 28:691–693PubMedCrossRefGoogle Scholar
  226. 226.
    Ungemack JA (1994) Patterns of personal health practice: men and women in the United States. Am J Prev Med 10:38–44:1994PubMedGoogle Scholar
  227. 227.
    United States Food and Drug Administration: Office of the Federal Register, National Archives and Records Administration (1995) Title 21, Code of Federal Regulations, 170.22. Safety factors to be considered. (Title 21, Code of Federal Regulations, Parts 170 to 1995). Office of the Federal Register US Government Printing Office, Washington, DCGoogle Scholar
  228. 228.
    Urgert R, van Vliet T, Zock PL, Katan MB (2000) Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. Am J Clin Nutr 72:1107–1110PubMedGoogle Scholar
  229. 229.
    Urso-Baiarda F, Shurey S, Grobbelaar AO (2007) Effect of caffeine on microsurgical technical performance. Microsurgery 27:84–87PubMedCrossRefGoogle Scholar
  230. 230.
    van Boxtel MP, Schmitt JA, Bosma H, Jolles J (2003) The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav 75:921–927PubMedCrossRefGoogle Scholar
  231. 231.
    van Dam RM, Feskens EJ (2002) Coffee consumption and risk of type 2 diabetes mellitus. [see comment]. Lancet 360:1477–1478PubMedCrossRefGoogle Scholar
  232. 232.
    van Dam RM, Pasman WJ, Verhoef P (2004) Effects of coffee consumption on fasting blood glucose and insulin concentrations: randomized controlled trials in healthy volunteers. Diabetes Care 27:2990–2992PubMedCrossRefGoogle Scholar
  233. 233.
    Van den Hoogen PC, Seidell JC, Menotti A, Kromhout D (2000) Blood pressure and long-term coronary heart disease mortality in the Seven Countries study: implications for clinical practice and public health. Eur Heart J 21:1639–42PubMedCrossRefGoogle Scholar
  234. 234.
    van Dusseldorp M, Katan MB (1990) Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. Br Med J 300:1558–1559CrossRefGoogle Scholar
  235. 235.
    van Dusseldorp M, Smits P, Thien T, Katan MB (1989) Effect of decaffeinated versus regular coffee on blood pressure. A 12-week, double-blind trial. Hypertension 14:563–569PubMedCrossRefGoogle Scholar
  236. 236.
    Van’t Hoff W (1982) Caffeine in pregnancy. Lancet 2:1020CrossRefGoogle Scholar
  237. 237.
    Vik T, Bakketeig LS, Trygg KU, Lund-Larsen K, Jacobsen G (2003) High caffeine consumption in the third trimester of pregnancy: gender-specific effects on fetal growth. Paediatric Perinatal Epidemiol 17:324–331CrossRefGoogle Scholar
  238. 238.
    Vitzthum OG (1976) Chemie und bearbeitung des kaffees. In: Eichler O (ed) Kaffee und coffein, 2nd edn. Springer, Berlin, pp 3–64CrossRefGoogle Scholar
  239. 239.
    Vlachopoulos C, Hirata K, O’Rourke MF (2003) Effect of caffeine on aortic elastic properties and wave reflection. J Hypertens 21:563–570PubMedCrossRefGoogle Scholar
  240. 240.
    Vlachopoulos C, Hirata K, Stefanadis C, Toutouzas P, O’Rourke MF (2003) Caffeine increases aortic stiffness in hypertensive patients. Am J Hypertens 16:63–66PubMedCrossRefGoogle Scholar
  241. 241.
    Vlachopoulos C, Kosmopoulou F, Panagiotakos D, Ioakeimidis N, Alexopoulos N, Pitsavos C et al (2004) Smoking and caffeine have a synergistic detrimental effect on aortic stiffness and wave reflections. J Am College Cardiol 44:1911–1917CrossRefGoogle Scholar
  242. 242.
    von Borstel RW, Wurtman RJ (1982) Caffeine withdrawal enhances sensitivity to physiologic level of adenosine in vivo. Federation Proc 41:1669Google Scholar
  243. 243.
    Wahrburg U, Martin H, Schulte H, Walek T, Assmann G (1994) Effects of two kinds of decaffeinated coffee on serum lipid profiles in healthy young adults. Eur J Clin Nutr 48:172–179PubMedGoogle Scholar
  244. 244.
    Watt AH, Bayer A, Routledge PA, Swift CG (1989) Adenosine-induced respiratory and heart rate changes in young and elderly adults. Br J Clin Pharmacol 27:265–267PubMedCrossRefGoogle Scholar
  245. 245.
    Weber JG, Ereth MH, Danielson DR (1993) Perioperative ingestion of caffeine and postoperative headache. Mayo Clinic Proc 368:842–845CrossRefGoogle Scholar
  246. 246.
    Weinstein ND (2007) Misleading tests of health behavior theories. [see comment]. Ann Behav Med 33(1):1–10PubMedCrossRefGoogle Scholar
  247. 247.
    Wen W, Shu XO, Jacobs DR Jr, Brown JE (2001) The associations of maternal caffeine consumption and nausea with spontaneous abortion. Epidemiology 12:38–42PubMedCrossRefGoogle Scholar
  248. 248.
    Weusten-Van der Wouw MP, Katan MB, Viani R, Huggett AC, Liardon R, Lund-Larsen PG, Thelle DS, Ahola I, Aro A, Meyboom S, Beynen AG (1994) Identity of the cholesterol-raising factor from boiled coffee and its effects on liver function enzymes. J Lipid Res 35:721–733PubMedGoogle Scholar
  249. 249.
    Whittemore AS, Wu ML, Paffenbarger RS Jr, Sarles DL, Kampert JB, Grosser S, Jung DL, Ballon S, Hendrickson M (1988) Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 128:1228–1240PubMedGoogle Scholar
  250. 250.
    Wilson PW, Culleton BF (1998) Epidemiology of cardiovascular disease in the United States. Am J Kidney Dis 32(5 Suppl 3):S56–S65PubMedCrossRefGoogle Scholar
  251. 251.
    Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F (2003) Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA: J Am Med Assoc 289:2363–2369CrossRefGoogle Scholar
  252. 252.
    World Health Organization (2007) International statistical classification of diseases and related health problems, 10th revision. WHO, GenevaGoogle Scholar
  253. 253.
    Zatonski WA, Boyle P, Przewozniak K, Maisonneuve P, Drosik K, Walker AM (1993) Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: a case-control study from Opole, Poland. Int J Cancer 53:601–607PubMedCrossRefGoogle Scholar
  254. 254.
    Zeltner T, Kessler DA, Martiny A, Randera F (2000) Tobacco company strategies to undermine tobacco control activities at the World Health Organization. World Health Organization, GenevaGoogle Scholar
  255. 255.
    Zheng W, McLaughlin JK, Gridley G, Bjelke E, Schuman LM, Silverman DT, Wacholder S, Co-Chien HT, Blot WJ, Fraumeni J Jr (1993) A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 4:477–482PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of PsychologyNational University of IrelandGalwayIreland

Personalised recommendations